← Back to screener

Theravance Biopharma, Inc. TBPH

Rank #2308 · Nasdaq · $0.9B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
25.1
P/E
-15.5
P/B
4.97
ROE
-32.1%
Op. Margin
-72.9%
Debt Ratio
102%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -15.5x, P/B 4.97x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -32.1%. Ranks in the top 86% of the universe.

Safety ★★★☆☆
Good

Debt ratio 102%. Ranks in the top 40% of the universe.

Growth ★★★★☆
Good

Revenue growth of 12.1% year over year. Ranks in the top 30% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014$0.1B$-0.0B$-0.0B$-0.1B-7.4-118
2015$0.0B$-0.2B$-0.2B$-0.0B-69152.2-4932
2016$0.0B$-0.2B$-0.2B$-0.0B-1989.6-1862
2017$0.0B$-0.2B$-0.2B$0.3B-431.8121
2018$0.0B$-0.2B$-0.2B$0.2B-371.082
2019$0.0B$-0.3B$-0.3B$0.4B-1690.660
2020$0.1B$-0.2B$-0.2B$0.1B-395.5255
2021$0.1B$-0.3B$-0.2B$-0.1B-343.1-1009
2022$0.1B$-0.3B$-0.3B$-0.2B-414.2-267
2023$0.1B$-0.1B$0.9B$-0.3B-179.1-279
2024$0.1B$-0.1B$-0.1B$0.4B-97.6-14
2025$0.1B$-0.0B$-0.1B$0.2B-72.9102

← See the full screener